Regeneron – MFN Drug Pricing Agreement

Summary Regeneron has entered into a ‘most favored nation’ (MFN) drug-pricing agreement with the White House, aligning certain drug prices with Medicaid benchmarks. The move reflects increasing policy pressure on pharmaceutical pricing rather than a scientific or clinical development. What Happened Regeneron agreed to participate…